| SC 13G/A | 2018-06-25 | Flynn James E | Aralez Pharmaceuticals Inc. | 5,372,885 | 5.0% | EDGAR |
| SC 13G/A | 2018-02-14 | PAR INVESTMENT PARTNERS LP | Aralez Pharmaceuticals Inc. | 5,942,309 | 8.9% | EDGAR |
| SC 13G/A | 2018-02-14 | Flynn James E | Aralez Pharmaceuticals Inc. | 5,372,885 | 7.5% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | Aralez Pharmaceuticals Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2017-02-14 | PAR INVESTMENT PARTNERS LP | Aralez Pharmaceuticals Inc. | 6,400,000 | 9.8% | EDGAR |
| SC 13G/A | 2017-02-14 | Flynn James E | Aralez Pharmaceuticals Inc. | 5,372,884 | 7.7% | EDGAR |
| SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | Aralez Pharmaceuticals Inc. | 4,791,590 | 7.3% | EDGAR |
| SC 13G | 2016-03-24 | Broadfin Capital, LLC | Aralez Pharmaceuticals Inc. | 3,800,000 | 5.9% | EDGAR |
| SC 13G | 2016-02-16 | PAR INVESTMENT PARTNERS LP | Aralez Pharmaceuticals Inc. | 3,863,699 | 5.2% | EDGAR |
| SC 13G | 2016-02-16 | Flynn James E | Aralez Pharmaceuticals Inc. | 5,373,569 | 7.8% | EDGAR |